Last reviewed · How we verify
RHEZ
RHEZ, a drug under development by Otsuka Pharmaceutical, is being evaluated for the treatment of tuberculosis, particularly in patients with HIV-associated severe immune suppression. The drug has completed several clinical trials, demonstrating potential efficacy and safety. Further studies are needed to establish its role in the treatment landscape.
At a glance
| Generic name | RHEZ |
|---|---|
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RHEZ CI brief — competitive landscape report
- RHEZ updates RSS · CI watch RSS
- Otsuka Pharmaceutical Development & Commercialization, Inc. portfolio CI